Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | ANPEP | P15144 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13661911 | 0.86 | ALDH1A1 (0.46) | PEPDMMP2ANPEPALDH1A1POLB | |
| SCHEMBL16376157 | 0.86 | ALDH1A1 (0.46) | PEPDMMP2ANPEPALDH1A1POLB | |
| SCHEMBL2608451 | 0.86 | ALDH1A1 (0.46) | PEPDMMP2ANPEPALDH1A1POLB | |
| SCHEMBL2610758 | 0.86 | ALDH1A1 (0.46) | PEPDMMP2ANPEPALDH1A1POLB | |
| SCHEMBL18084393 | 0.86 | ALDH1A1 (0.46) | PEPDMMP2ANPEPALDH1A1POLB | |
| SCHEMBL18084388 | 0.81 | MMP2 (0.38) | MMP2ANPEPALDH1A1POLBCYP3A4 | |
| SCHEMBL85520 | 0.81 | MMP2 (0.38) | MMP2ANPEPALDH1A1POLB | |
| SCHEMBL12795646 | 0.81 | MMP2 (0.38) | MMP2ANPEPALDH1A1POLB | |
| SCHEMBL15760313 | 0.80 | ATM (0.32) | — | |
| SCHEMBL9969991 | 0.77 | ALDH1A1 (0.40) | MMP2ANPEPALDH1A1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312473-A1 | PROCESS FOR THE PREPARATION OF BIHETEROARYL COMPOUNDS AND CRYSTAL FORMS THEREOF | GENENTECH, INC. (US) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312473-A1 | PROCESS FOR THE PREPARATION OF BIHETEROARYL COMPOUNDS AND CRYSTAL FORMS THEREOF | NONO, PNPO, KMO | PEPD 482/4885MMP2 4081/4885ANPEP 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.